IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 859日前
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 410日前
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 592日前
Swiss Market Ends Sharply Lower On Trade War Fears

Swiss Market Ends Sharply Lower On Trade War Fears

Swiss stocks fell sharply on Friday, mirroring losses across Europe and elsewhere, as the Trump Administration's sweeping tariffs on trade partners, and retaliatory move announced by China, and possible countermeasures by a few other major countries as well, raised fears of a possible global recession.
RTTNews | 18時24分前
European Stocks Tumble As China Retaliates After Trump's Tariff Moves

European Stocks Tumble As China Retaliates After Trump's Tariff Moves

European stocks plunged sharply and several market tumbled to fresh multi-month lows on Friday as U.S. President Donald Trump's sweeping tariff moves, and the retaliatory action by China raised fears of a global trade war and recession, prompting investors to press sales across the board.
RTTNews | 18時44分前